sevoflurane anesthetics
PreclinicalSmall molecule
sevoflurane anesthetics is one of 15 small molecule programs targeting Biliary Atresia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Biliary Atresia
#DrugCompanyPhaseTrials
1Anjeso
Boehringer IngelheimApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Bylvay
IpsenPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 2
Trental
VValidus Pharmaceuticals
Phase 2
Immunoglobulin
SanofiPhase 2
Livmarli
MMirum Pharmaceuticals, Inc.
Phase 2
N-Acetyl Cyteien
SStanford University
Phase 2
Granulocyte Colony-Stimulating Factor
SanofiPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Biliary Atresia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sevoflurane anesthetics. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYonsei University